Role of Spectral CT in the Evaluation of Cardiotoxicity in Patients With Hodgkin's Lymphoma and Diffuse Large B-cell Lymphoma Treated With Anthracyclines

Launched by IRCCS AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA · Jan 9, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at a special type of imaging called Spectral CT to see how well it can detect heart problems caused by certain cancer treatments in patients with Hodgkin's lymphoma and diffuse large B-cell lymphoma. These patients often receive a chemotherapy drug called anthracycline, which can sometimes harm the heart. By using Spectral CT with a contrast agent (a special dye), the researchers hope to identify any early signs of heart damage during routine follow-up appointments.

To participate in this trial, you need to be at least 18 years old and currently receiving treatment for Hodgkin's lymphoma or diffuse large B-cell lymphoma that includes anthracyclines. However, if you have certain health issues, like severe kidney problems or a history of serious heart conditions, you won't be able to take part. If you join the study, you'll undergo the Spectral CT imaging as part of your regular check-ups, helping doctors understand how to better monitor heart health in cancer patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with Hodgkin's lymphoma or diffuse large B-cell lymphoma (DLBCL) undergoing treatment regimens including anthracyclines
• • Age ≥18 years
• • Informed consent obtained
• Exclusion Criteria:
• • Absolute or relative contraindications to CT examination and/or administration of iodinated contrast agents (e.g., pregnancy, severe renal insufficiency in non-dialysis patients with GFR \<15-30 ml/min/1.73m²).
• • Patients with a concomitant positive history of cardiovascular disease (e.g., myocardial infarction, known coronary artery disease, heart failure, arrhythmias, prior myocarditis, cardiomyopathies).
• • History of mediastinal radiotherapy.